Quantum Biopharma (QNTM) Competitors $18.08 +0.03 (+0.17%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$18.74 +0.66 (+3.62%) As of 08/22/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock QNTM vs. VOR, ALMS, IMMP, TKNO, SCPH, ALLO, SGMT, SOPH, AARD, and FENCShould you be buying Quantum Biopharma stock or one of its competitors? The main competitors of Quantum Biopharma include Vor Biopharma (VOR), Alumis (ALMS), Prima BioMed (IMMP), Alpha Teknova (TKNO), scPharmaceuticals (SCPH), Allogene Therapeutics (ALLO), Sagimet Biosciences (SGMT), SOPHiA GENETICS (SOPH), Aardvark Therapeutics (AARD), and Adherex Technologies (FENC). These companies are all part of the "pharmaceutical products" industry. Quantum Biopharma vs. Its Competitors Vor Biopharma Alumis Prima BioMed Alpha Teknova scPharmaceuticals Allogene Therapeutics Sagimet Biosciences SOPHiA GENETICS Aardvark Therapeutics Adherex Technologies Vor Biopharma (NYSE:VOR) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment. Which has higher earnings & valuation, VOR or QNTM? Quantum Biopharma is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVor BiopharmaN/AN/AN/A-$13.66-0.16Quantum BiopharmaN/AN/A-$14.20M-$14.02-1.29 Do institutionals & insiders have more ownership in VOR or QNTM? 97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 0.5% of Vor Biopharma shares are owned by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is VOR or QNTM more profitable? Vor Biopharma's return on equity of 0.00% beat Quantum Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Vor BiopharmaN/A N/A N/A Quantum Biopharma N/A -270.22%-131.87% Which has more volatility & risk, VOR or QNTM? Vor Biopharma has a beta of 2.06, suggesting that its share price is 106% more volatile than the S&P 500. Comparatively, Quantum Biopharma has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Do analysts recommend VOR or QNTM? Vor Biopharma currently has a consensus price target of $6.07, indicating a potential upside of 179.57%. Given Vor Biopharma's stronger consensus rating and higher possible upside, research analysts plainly believe Vor Biopharma is more favorable than Quantum Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vor Biopharma 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.56Quantum Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer VOR or QNTM? In the previous week, Vor Biopharma had 14 more articles in the media than Quantum Biopharma. MarketBeat recorded 15 mentions for Vor Biopharma and 1 mentions for Quantum Biopharma. Vor Biopharma's average media sentiment score of 0.12 beat Quantum Biopharma's score of 0.00 indicating that Vor Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Quantum Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryVor Biopharma beats Quantum Biopharma on 10 of the 12 factors compared between the two stocks. Get Quantum Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for QNTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QNTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNTM vs. The Competition Export to ExcelMetricQuantum BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.48M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-1.2920.8831.1026.04Price / SalesN/A343.33433.45102.77Price / CashN/A43.1937.7358.48Price / Book25.838.129.536.61Net Income-$14.20M-$54.72M$3.26B$265.56M7 Day Performance-19.47%2.63%2.10%1.97%1 Month Performance-20.14%2.78%2.81%-0.36%1 Year PerformanceN/A11.01%30.56%19.03% Quantum Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNTMQuantum BiopharmaN/A$18.08+0.2%N/AN/A$52.48MN/A-1.29N/AVORVor Biopharma1.9694 of 5 stars$2.04-4.7%$6.07+197.4%+135.9%$258.43MN/A-1.24140ALMSAlumis2.4518 of 5 stars$4.85+2.1%$20.17+315.8%-62.5%$258.43MN/A0.00N/AIMMPPrima BioMed1.0223 of 5 stars$1.78+2.9%$7.00+293.3%-26.3%$253.94MN/A0.002,021Upcoming EarningsTKNOAlpha Teknova1.7053 of 5 stars$4.41-6.0%$10.00+126.8%-3.5%$250.99M$37.74M-10.50240SCPHscPharmaceuticals4.5493 of 5 stars$4.78+3.9%$14.00+192.9%-5.6%$245.17M$49.97M-2.6430Short Interest ↓ALLOAllogene Therapeutics2.8462 of 5 stars$1.09-0.9%$8.44+674.7%-54.1%$244.07M$20K-0.98310SGMTSagimet Biosciences3.2428 of 5 stars$7.55-1.6%$25.67+240.0%+144.3%$235.28M$2M-4.138SOPHSOPHiA GENETICS2.9803 of 5 stars$3.49+0.6%$8.00+129.2%+2.0%$234.50M$65.17M-7.93520Positive NewsGap UpAARDAardvark TherapeuticsN/A$10.44-3.2%$32.80+214.2%N/A$233.89MN/A0.0018News CoverageAnalyst RevisionFENCAdherex Technologies1.8456 of 5 stars$8.20-1.9%$13.33+62.6%+57.5%$232.53M$33.30M-19.5210News CoverageAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Vor Biopharma Alternatives Alumis Alternatives Prima BioMed Alternatives Alpha Teknova Alternatives scPharmaceuticals Alternatives Allogene Therapeutics Alternatives Sagimet Biosciences Alternatives SOPHiA GENETICS Alternatives Aardvark Therapeutics Alternatives Adherex Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNTM) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quantum Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quantum Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access